Can a Growth-Hormone blocker stay safe in everyday use? a korean study investigates

NCT ID NCT05131100

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This observational study tracks patients in Korea who have been prescribed Somavert (pegvisomant) for acromegaly, a condition caused by too much growth hormone. Researchers will monitor side effects and whether patients show clinical improvement during routine treatment. The goal is to see how the drug performs in real-world settings outside of controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Somavert (pegvisomant)
What this could lead to: If the data confirm real-world safety and effectiveness, it may support continued use of Somavert for acromegaly in routine practice.
What could go wrong: This is a small observational study with only 11 participants, so findings may not apply broadly. No new treatment or comparison is being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acromegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACROMEGALY

Contacts and locations

Show contact details

Locations

Pfizer

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.